Related Experiment Videos
Childhood acute lymphoblastic leukemia
Ching-Hon Pui1, Mary V Relling, Dario Campana
1Department of Hematology-Oncology, St. Jude Children's Research Hospital, and Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. ching-hon.Pui@stjude.org
Abstract:
As cure rates in childhood acute lymphoblastic leukemia reach 80%, emphasis is increasingly placed on the accurate identification of drug-resistant cases, the elucidation of the mechanisms involved in drug resistance and the development of new therapeutic strategies targeted toward the pivotal molecular lesions. Pharmacodynamic and pharmacogenomic studies have provided rational criteria for individualizing therapy to enhance efficacy and reduce acute toxicity and late sequelae. Currently, assessment of the early response to treatment by measurement of minimal residual disease (MRD) is the most powerful independent prognostic indicator. MRD is affected by both the drug sensitivity of leukemic cells and the pharmacodynamic and pharmacogenetic properties of the host cells. Rapid advances in biotechnology and bioinformatics should ultimately facilitate the development of molecular diagnostic assays that can be used to optimize antileukemic therapy and elucidate the mechanisms of leukemogenesis. In the interim, prospective clinical trials have provided valuable clues that are further increasing the cure rate of childhood acute lymphoblastic leukemia.
Insights
Identifying drug-resistant childhood leukemia is key as cure rates rise. Measuring minimal residual disease (MRD) helps tailor treatments and improve outcomes for acute lymphoblastic leukemia.
Area of Science:
- Pediatric Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Childhood acute lymphoblastic leukemia (ALL) cure rates are improving, nearing 80%.
- Focus is shifting towards identifying and overcoming drug resistance in ALL.
- Understanding resistance mechanisms is crucial for developing targeted therapies.
Purpose of the Study:
- To highlight the importance of identifying drug-resistant ALL cases.
- To emphasize the role of pharmacodynamic and pharmacogenomic studies in personalizing ALL therapy.
- To discuss the prognostic significance of minimal residual disease (MRD) assessment.
Main Methods:
- Review of pharmacodynamic and pharmacogenomic studies.
- Analysis of minimal residual disease (MRD) as a prognostic indicator.
- Discussion of advances in biotechnology and bioinformatics for molecular diagnostics.
Main Results:
- Minimal residual disease (MRD) measurement is the strongest independent prognostic factor in ALL.
- MRD is influenced by leukemic cell drug sensitivity and host genetic factors.
- Individualized therapy based on pharmacogenomics can enhance efficacy and reduce toxicity.
Conclusions:
- Accurate identification of drug resistance and understanding its mechanisms are vital for improving ALL outcomes.
- Minimal residual disease (MRD) monitoring is essential for prognostication and treatment individualization.
- Continued research and clinical trials are advancing the cure rates for childhood ALL.